Investors comparing SCHD and VHT are not choosing between two near-identical products. These funds represent fundamentally different ways of pursuing defensive, income-oriented exposure. SCHD is a broad, dividend-focused portfolio that draws income from multiple industries, while VHT is a pure-play vehicle concentrated in a single, economically resilient sector. They compete for the same investor dollar — those seeking lower volatility and steady total return — but deliver it through very different paths. Understanding that structural gap is essential before evaluating either fund's relative positioning in the current market cycle. I also checked sector overlaps using Tickeron’s AI Screener to see how the holdings line up across industries.
SCHD is a passively managed exchange-traded fund (ETF) that tracks the Dow Jones U.S. Dividend 100 Index. The underlying index screens for companies with strong dividend track records, solid cash flow, and healthy balance sheets, emphasizing both dividend yield and dividend sustainability. The fund typically holds around 100–104 stocks, weighted by market capitalization with caps to limit concentration.
Top holdings recently included Merck & Co. (MRK), Abbott Laboratories (ABT), Amgen (AMGN), Coca-Cola (KO), Home Depot (HD), Chevron (CVX), ConocoPhillips (COP), UnitedHealth Group (UNH), Procter & Gamble (PG), and Texas Instruments (TXN). Sector exposure skews defensive: energy and consumer staples each approach 19–20%, health care roughly 16%, with industrials and financials filling out the balance. Its 0.06% expense ratio makes it one of the cheapest dividend funds available, and the index is reconstituted annually. From what I see, the emphasis on sustainability gives it a steady profile worth monitoring.
VHT is a passively managed ETF that tracks the MSCI US Investable Market Health Care 25/50 Index. The fund provides broad, market-cap-weighted exposure to large-, mid-, and small-cap U.S. health care companies, holding roughly 420–440 securities. It is one of the most comprehensive, lowest-cost ways to own the entire U.S. health care complex in a single position.
Nearly 100% of the portfolio sits in the health care sector, spanning pharmaceuticals, biotechnology, medical devices, health insurers, and managed care. Top holdings are heavily weighted toward mega-cap pharma: Eli Lilly (LLY) at roughly 13%, Johnson & Johnson (JNJ) near 9%, AbbVie (ABBV) around 6%, followed by Merck (MRK), UnitedHealth Group (UNH), Thermo Fisher Scientific (TMO), Amgen (AMGN), Abbott Laboratories (ABT), Gilead Sciences (GILD), and Pfizer (PFE). The fund charges a 0.09% expense ratio and uses full replication to mirror its benchmark. I’m watching this closely because the concentration in a few names can amplify both upside and downside moves.
The two funds sit in very different thematic currents. SCHD's fortune is tied to the broader dividend and value complex — energy prices, consumer staples pricing power, and the level of interest rates that shape how investors value income-producing equities. When yield becomes scarce or defensive rotation accelerates, SCHD tends to attract capital flows.
VHT, by contrast, is driven by health care-specific catalysts. Innovation in GLP-1 weight-loss and diabetes therapies has propelled select mega-caps, while an aging global population underpins durable demand for pharmaceuticals and managed care. At the same time, the sector carries idiosyncratic risks: drug-pricing reform, regulatory scrutiny, patent expirations, and clinical-trial outcomes. Macro factors such as interest-rate expectations and merger-and-acquisition activity in biotech also shape sentiment. Both funds offer defensive characteristics, but VHT concentrates that defense in a single, innovation-driven industry.
In recent market cycles, the two funds have diverged meaningfully. SCHD's value and dividend orientation has lagged growth-heavy benchmarks, as its energy, staples, and financials weightings offered income but limited participation in technology-led rallies. Its below-market beta has kept drawdowns relatively shallow, reinforcing its role as a stability-oriented sleeve rather than a momentum vehicle.
VHT has benefited from strong performance among its largest holdings. Mega-cap pharmaceutical and health care names such as Eli Lilly, Johnson & Johnson, and AbbVie have posted robust gains over the trailing year, lifting the fund's returns and supporting consistent relative momentum. However, this concentration cuts both ways: a setback in any top holding can weigh disproportionately on the fund. From what I see, VHT has exhibited stronger trend consistency in recent months, while SCHD has offered lower volatility and higher income but weaker price momentum.
One resource I turn to regularly is Tickeron’s AI Screener. It lets me filter ETFs and stocks by technical patterns, fundamentals, trends, volatility, and AI-driven signals, which helps surface relative strength and breakout ideas more efficiently than manual checks. For side-by-side evaluations like this one, the tool provides a structured way to compare momentum before making allocation decisions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The 10-day moving average for SCHD crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on SCHD as a result. In 67 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for SCHD just turned positive on November 13, 2026. Looking at past instances where SCHD's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
SCHD moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCHD advanced for three days, in 265 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 282 of 364 cases where SCHD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
The 10-day RSI Indicator for SCHD moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 30 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCHD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
SCHD broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows